A new study published in JAMA suggests that a blood test measuring the protein p-tau217 can help identify healthy older adults at high risk of developing Alzheimer's symptoms within the next five to 10 years. Researchers found that individuals with very high baseline levels of this protein faced a 38% risk of cognitive impairment within five years, a figure that climbed to 78% over a decade. This predictive capability was found to be independent of other common risk factors, such as amyloid plaque presence or specific genetic markers like APOE4.
While these findings represent a significant step in Alzheimer's research, medical experts emphasize that the test is not currently intended for routine use in healthy, asymptomatic individuals. The p-tau217 test is already utilized in clinical settings to help diagnose whether patients currently experiencing memory or thinking problems have Alzheimer's or another condition. However, because there are no approved treatments to prevent the disease in its pre-clinical stages, doctors caution that a positive result for a healthy person would not currently change their standard medical care.
For now, the primary value of this test lies in its potential to accelerate drug development. By identifying high-risk individuals, researchers can more efficiently enroll participants into clinical trials for experimental preventive treatments. If these trials successfully demonstrate that certain drugs can delay or prevent the onset of symptoms, the test could eventually become a vital tool for determining who might benefit from such interventions.
Until then, the medical community maintains that the best approach for brain health remains focused on established lifestyle habits. Experts continue to recommend regular cardiovascular exercise, a nutritious diet, consistent sleep, and staying mentally and socially engaged as the most effective ways to support long-term cognitive health.